ABUS — Arbutus Biopharma Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1447028 ·
Last close
$4.05
Market Cap
$620.84M
52W High
$5.45
52W Low
$3.50
ADV30
2,742,278
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 1,014,000 | — | -5,751,000 | -5,143,000 | 274,025,000 | 19,171,000 | 15,292,000 |
| Mar 2026 | 179,126,000 | — | 169,117,000 | 169,695,000 | 277,164,000 | 23,706,000 | 16,987,000 |
| Dec 2025 | 1,051,000 | — | -7,644,000 | -3,756,000 | 94,618,000 | 18,008,000 | 18,042,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$221,004,000
Investing CF
$-319,000
Financing CF
$21,113,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.10
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,156,406,000
Inventory
—
Receivables
$792,000
ST Investments
$73,299,000
EBIT TTM
$219,975,000
Pretax Income TTM
$219,911,000
Interest Exp TTM
$64,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$181,490,000
EBITDA
$145,492,000
Free Cash Flow
$334,960,640
Enterprise Value
$292,786,656
Total Cash
$337,489,984
Total Debt
$3,309,000
Shares Out
153,292,826
Trailing EPS
$1.12
Book Value
$0.43
ROE
269.6%
ROA
41.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 14,083,000 | -27,051,000 | -33,501,000 | 94,618,000 | 18,042,000 | 76,576,000 | -39,637,000 |
| Dec 2024 | 6,171,000 | -69,974,000 | -69,920,000 | 131,707,000 | 34,341,000 | 97,366,000 | -64,850,000 |
| Dec 2023 | 18,141,000 | -78,034,000 | -72,849,000 | 144,401,000 | 38,383,000 | 106,018,000 | -85,936,000 |
| Dec 2022 | 39,019,000 | -63,223,000 | -69,456,000 | 195,419,000 | 58,567,000 | 136,852,000 | -35,356,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$181,720,000
NetIncome TTM
$153,054,000
OpCashFlow TTM
—
Assets (Latest)
$274,025,000
Forward EPS
$-0.17
Max Pain — expiry 2027-01-15
max pain strike: $4.00 · spot: $4.11 · call oi: 2,323 · put oi: 547
Expected Move to 2027-01-15:
±$0.90
(21.90%) —
implied range
$3.21 –
$5.01
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALMS | ALUMIS INC. | $628.33M | $4.84 | — |
| DSGN | Design Therapeutics, Inc. | $630.12M | $9.84 | — |
| OLMA | Olema Oncology, Inc. | $632.52M | $7.22 | — |
| BCAX | Bicara Therapeutics Inc. | $637.32M | $9.60 | — |
| IMMX | Immix Biopharma, Inc. | $603.45M | $7.20 | — |
News headlines (Yahoo Finance, 1h cache)
Could Expanded Patent Lawsuits Change The Bull Case For BioNTech (BNTX)?
2026-11-13 10:14 · Yahoo
BioNTech (BNTX) Dropped, So What Is Driving Attention Now?
2026-11-13 09:11 · Yahoo
Arbutus: Q3 Earnings Snapshot
2026-11-10 12:36 · Yahoo
Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-10 12:30 · Yahoo
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
2026-10-22 11:30 · Yahoo
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
2026-10-01 11:30 · Yahoo
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
2026-09-30 11:30 · Yahoo
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan
2026-08-21 13:32 · Yahoo
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
2026-08-21 11:30 · Yahoo
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?
2026-08-11 00:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.